Trexquant Investment LP Buys 95,146 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Trexquant Investment LP boosted its stake in shares of Cryoport, Inc. (NASDAQ:CYRXFree Report) by 440.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,737 shares of the company’s stock after buying an additional 95,146 shares during the quarter. Trexquant Investment LP owned approximately 0.24% of Cryoport worth $1,808,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Cryoport by 13.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock valued at $157,000 after buying an additional 1,395 shares in the last quarter. WINTON GROUP Ltd bought a new stake in Cryoport during the 3rd quarter valued at about $163,000. Pathstone Family Office LLC purchased a new position in Cryoport during the 3rd quarter valued at about $165,000. Quantbot Technologies LP increased its position in Cryoport by 109.0% during the 3rd quarter. Quantbot Technologies LP now owns 12,838 shares of the company’s stock valued at $176,000 after purchasing an additional 6,694 shares during the period. Finally, Arizona State Retirement System increased its position in Cryoport by 5.4% during the 4th quarter. Arizona State Retirement System now owns 13,665 shares of the company’s stock valued at $212,000 after purchasing an additional 696 shares during the period. Institutional investors own 92.90% of the company’s stock.

Cryoport Stock Up 1.8 %

NASDAQ:CYRX opened at $11.04 on Monday. The company has a market cap of $543.83 million, a PE ratio of -4.47 and a beta of 1.60. Cryoport, Inc. has a twelve month low of $9.00 and a twelve month high of $23.50. The company has a current ratio of 10.73, a quick ratio of 10.22 and a debt-to-equity ratio of 0.86. The company’s 50 day moving average is $15.92 and its two-hundred day moving average is $15.47.

Cryoport (NASDAQ:CYRXGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The company had revenue of $54.59 million for the quarter, compared to analysts’ expectations of $58.78 million. Cryoport had a negative return on equity of 15.19% and a negative net margin of 50.17%. The firm’s revenue for the quarter was down 13.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.16) EPS. Analysts anticipate that Cryoport, Inc. will post -1.37 EPS for the current year.

Insiders Place Their Bets

In other Cryoport news, Director Richard J. Berman sold 8,105 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total transaction of $108,688.05. Following the sale, the director now owns 100,000 shares of the company’s stock, valued at approximately $1,341,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Cryoport news, CEO Jerrell Shelton sold 57,039 shares of Cryoport stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $15.30, for a total transaction of $872,696.70. Following the completion of the sale, the chief executive officer now directly owns 634,352 shares in the company, valued at approximately $9,705,585.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard J. Berman sold 8,105 shares of Cryoport stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total transaction of $108,688.05. Following the sale, the director now owns 100,000 shares of the company’s stock, valued at $1,341,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 85,488 shares of company stock valued at $1,302,259. Insiders own 10.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Cryoport in a research report on Wednesday, May 8th. B. Riley downgraded shares of Cryoport from a “buy” rating to a “neutral” rating and cut their target price for the company from $22.00 to $19.00 in a research report on Friday, May 3rd. Jefferies Financial Group initiated coverage on shares of Cryoport in a research report on Thursday, April 4th. They set a “buy” rating and a $21.00 target price on the stock. UBS Group lifted their price objective on shares of Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research report on Friday, March 15th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $17.00 price objective on shares of Cryoport in a research report on Wednesday, March 13th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $18.25.

Read Our Latest Analysis on Cryoport

About Cryoport

(Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

See Also

Institutional Ownership by Quarter for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.